HLA-C and psoriasis: Finally, we note that our findings appeared to be independent of HLA-C*06:02 status, which not only makes the strongest genetic contribution to psoriasis susceptibility (37) but critically also predicts response to both adalimumab and the IL-12/23 inhibitor ustekinumab (38).